1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 1,267 results.

$Thumbnail for Mezigdomide, Carfilzomib, and Dexamethasone (MeziKd) vs Carfilzomib and Dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma (RRMM): Results From the Phase 3 SUCCESSOR-2 Trial$

MM - 569

Mezigdomide, Carfilzomib, and Dexamethasone (MeziKd) vs Carfilzomib and Dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma (RRMM): Results From the Phase 3 SUCCESSOR-2 Trial

Meletios A Dimopoulos

Poster Presenter: Meletios A Dimopoulos

$Thumbnail for Reducing Hospitalization During Bispecific Antibody Initiation in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Pooled Analysis of Outpatient, Step-Up, and CRS-Mitigation Strategies$

MM - 574

Reducing Hospitalization During Bispecific Antibody Initiation in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Pooled Analysis of Outpatient, Step-Up, and CRS-Mitigation Strategies

Ayse Gul Korkmaz

Poster Presenter: Ayse Gul Korkmaz

Thumbnail for Iberdomide, Daratumumab, and Dexamethasone (IberDd) in Transplant-Ineligible/Deferred (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Updated Results From the CC-220-MM-001 Trial

MM - 578

Iberdomide, Daratumumab, and Dexamethasone (IberDd) in Transplant-Ineligible/Deferred (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Updated Results From the CC-220-MM-001 Trial

Abdullah Khan

Poster Presenter: Abdullah Khan

MM - 579

Ionized Calcium Outperforms Corrected Calcium for Hypercalcemia Assessment in Multiple Myeloma

Mario Alberto Ochoa Rodriguez

Poster Presenter: Mario Alberto Ochoa Rodriguez

$Thumbnail for Phase 3, Randomized Study of Talquetamab (Tal) Plus Daratumumab (Dara) ± Pomalidomide (Pom) vs Dara Plus Pom and Dexamethasone (DPd) in Relapsed/Refractory Multiple Myeloma (RRMM): MonumenTAL-3$

MM - 593

Phase 3, Randomized Study of Talquetamab (Tal) Plus Daratumumab (Dara) ± Pomalidomide (Pom) vs Dara Plus Pom and Dexamethasone (DPd) in Relapsed/Refractory Multiple Myeloma (RRMM): MonumenTAL-3

Omik Patel

Poster Presenter: Omik Patel

$Thumbnail for Post-BCMA Sequencing in Relapsed/Refractory Multiple Myeloma: BCMA Re-Targeting Versus Non-BCMA T-Cell Redirection$

MM - 605

Post-BCMA Sequencing in Relapsed/Refractory Multiple Myeloma: BCMA Re-Targeting Versus Non-BCMA T-Cell Redirection

Ayse Gul Korkmaz

Poster Presenter: Ayse Gul Korkmaz

$Thumbnail for Treatment Selection and Sequencing Preferences for Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Comparative Survey of Advanced Practice Providers and Physicians$

MM - 608

Treatment Selection and Sequencing Preferences for Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Comparative Survey of Advanced Practice Providers and Physicians

Blaise Nwotchouang

Poster Presenter: Blaise Nwotchouang

$Thumbnail for Updated Safety of Isatuximab Subcutaneous At-Home Administration by On-Body Injector in Relapsed/Refractory Multiple Myeloma in the Phase 3 IRAKLIA Study$

MM - 609

Updated Safety of Isatuximab Subcutaneous At-Home Administration by On-Body Injector in Relapsed/Refractory Multiple Myeloma in the Phase 3 IRAKLIA Study

Sloan Smith

Poster Presenter: Sloan Smith

Thumbnail for Expression Levels of lncRNA DANCR and lncRNA MIR17HG in Patients with Multiple Myeloma: Relation to Disease Characteristics and Other Prognostic Markers.

MM - 611

Expression Levels of lncRNA DANCR and lncRNA MIR17HG in Patients with Multiple Myeloma: Relation to Disease Characteristics and Other Prognostic Markers.

Maha Elgammal

Poster Presenter: Maha Elgammal